{"id":"W3186488369","doi":"10.1016/j.jtho.2021.07.008","title":"Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Janssen Pharmaceuticals; Foundation Medicine; EMD Serono; Genentech; G1 Therapeutics; Puma Biotechnology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Pfizer; Incyte; F. Hoffmann-La Roche; AbbVie; Daiichi-Sankyo; Teva Pharmaceutical Industries; Roche; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen","keywords":"Medicine; Alectinib; Internal medicine; Clinical endpoint; Oncology; Cohort; Asymptomatic; Confidence interval; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Clinical trial; Phases of clinical research; Crizotinib; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003635223,0.000886018,0.001417485,0.0003547479,0.0003222825,0.0007930184,0.0004988501,0.0007105843,0.0018954],"category_scores_gemma":[0.002413583,0.0002568014,0.0008621291,0.0003787072,0.0003862419,0.0006360184,0.0004471308,0.001135097,0.0004498291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006771687,"about_ca_system_score_gemma":0.001038346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001252821,"about_ca_topic_score_gemma":0.002702761,"domain_scores_codex":[0.9990253,0.0006541054,0.00003431615,0.00009408002,0.0001132256,0.00007886624],"domain_scores_gemma":[0.9988192,0.0003089707,0.0003001927,0.00008929445,0.0001311911,0.0003511659],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7717928,0.01218109,0.07457811,0.0007455561,0.001891974,0.0004058071,0.0003312117,0.002448521,0.01641648,0.0002781611,0.009627216,0.109303],"study_design_scores_gemma":[0.5556158,0.222425,0.203085,0.0001432462,0.00188063,0.001175855,0.0001155711,0.003557246,0.00321757,0.0005947975,0.008079555,0.0001098958],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933575,0.002359102,0.0003866566,0.0004583862,0.00004903777,0.0005592473,0.00180469,0.00006974454,0.0009557092],"genre_scores_gemma":[0.9838821,0.001599004,0.001876721,0.000773887,0.0001668379,0.001359843,0.008501093,0.0000361912,0.001804319],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003635223,"threshold_uncertainty_score":0.01922518,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04395250547035683,"score_gpt":0.4840153234446429,"score_spread":0.440062817974286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}